ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of Urothelial Cancer
Shots:
- The first patient has been dosed in the P-I study (ASPEN-07) evaluating ALX148 (evorpacept) + Padcev (enfortumab vedotin-ejfv) in 30 patients with UC. The study will evaluate the safety, tolerability, PK & PD
- Evorpacept showed a promising clinical response across a range of hematologic and solid malignancies in combination with leading anti-cancer agents
- Evorpacept's clinical development will also be continued for the treatment of multiple solid tumor indications and hematologic malignancies. Evorpacept is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain
Ref: ALX Oncology | Image: ALX Oncology
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
